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Abstract
Background: Multiple new targeted agents have been developed for patients with human epidermal growth
factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop
brain metastases with greater incidence than patients with non-HER2 cancers, and many of them will undergo
stereotactic radiosurgery (SRS) or other CNS radiotherapy. The interaction between radiation effects and new
targeted agents is not well understood. We report two cases suggesting a novel adverse effect of T-DM1
(trastuzumab emtansine) on symptomatic enlargement of radiation necrosis (RN) after SRS.
Case presentation: Two patients with HER2-positive breast cancer had received SRS for single brain metastasis
more than 5-years ago. They had been heavily treated for HER2-positive metastatic breast cancer (trastuzumab
and pacritaxel, lapatinib and capecitabine). They initiated T-DM1 therapy for progressive systematic disease 5.
5 years after stereotactic irradiation, when a small RN was recognized on brain MR images of each patient.
The RN lesions increased in size and became symptomatic during 13 or 14 months of T-DM1 treatment. The
patients underwent surgical resection of the lesion. Pathological examination revealed necrosis, hematoma,
granulation tissue and telangiectasia without neoplastic cells.
Conclusions: A potential enhancement of RN by T-DM1 in the brain may be one of important adverse events
associated with the use of T-DM1 for patients after SRS. These cases highlight the need of careful follow-up
when combining new systemic targeted therapies and SRS for brain metastases.
Keywords: Brain metastasis, Breast cancer, Human epidermal growth factor receptor type 2, Radiation necrosis,
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Background
T-DM1 (Trastuzumab emtansine) is an antibody–drug
conjugate combining the human epidermal growth fac-
tor receptor type 2 (HER2) - targeted monoclonal anti-
body, trastuzumab, with the microtubule inhibitor
mertansine (DM1). Through the combined effect of in-
hibition of HER2 signaling and delivery of a cytotoxic
agent to HER2 expressing cells, T-DM1 demonstrated
improved progression-free and overall survival in patients
with HER2-positive metastatic breast cancer. The most
frequently reported adverse events of T-DM1 include
fatigue, nausea, diarrhea, elevated transaminases, anemia,
thrombocytopenia, and hemorrhage [1, 2]. Increased
brain edema has been reported shortly after T-DM1 in-
fusion in patients who received stereotactic radiosur-
gery (SRS) at a median of 8.5 days prior to the infusion,
with potential interactions between T-DM1 and SRS
[3]. Herein, we present two cases of histologically
proven delayed cerebral radiation necrosis with rapid
symptomatic growing mass sign associated with T-DM1




A 67-year-old woman presented with a-week history of
progressive sensory aphasia. Magnetic resonance im-
aging (MRI) of the brain showed a heterogeneous mass
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lesion in the left temporal lobe, which was increasing in
size (Fig. 1a–c). Perfusion computed tomography (CT)
of the head showed a decrease in cerebral blood volume
(CBV) in the mass lesion (Fig. 1d).
Eight years earlier, the patient had presented with an
inflammatory breast cancer of the left with estrogen re-
ceptor (ER) negative (0 %), progesterone receptor nega-
tive (0 %), HER2 positive (3+) and Ki67 unavailable.
T4dN2M1 (HEP), stage IV and tumor size was 7 cm ×
7.5 cm at initial diagnosis. She underwent the first-line
chemotherapy as a palliation. She received 13 cycles of
weekly paclitaxel with trastuzumab. At the time of dis-
ease progression, a screening brain MRI disclosed an
asymptomatic brain metastasis (BM), 8 mm in diam-
eter, in the left temporal lobe, and she underwent SRS
(D95 = 25 Gy) for the BM. She received vinorelbine
with trastuzumab, lapatinib with capecitabine, and
weekly trastuzumab as palliative regimens. After 3 years
from initial diagnosis, she underwent left mastectomy
and was followed by radiotherapy against the chest wall
with the aim of local control. Trastuzumab monotherapy
was resumed as a systemic therapy, however, mediastinal
lymph node and adrenal metastases were disclosed. She
received lapatinib plus capecitabine therapy as treatment
for the progression.
Approximately 6.5 years after initial diagnosis and
5.5 years after SRS, the patient received T-DM1, as a
newly approved targeted agent. She received 3.6 mg per
kilogram of body weight intra venously every 21 days.
Her systemic metastases were then well controlled. Eight
months after the initiation of T-DM1, a follow-up MRI
revealed an asymptomatic cyst and nodular lesion at the
irradiation site, which increased in size consistently
(Fig. 1b). Cytological examination of the cyst fluid was
negative for neoplastic cells. The images and cytological
results were consistent with symptomatic RN. The pa-
tient underwent surgical resection of the mass lesion
14 months after the initiation of T-DM1. The patho-
logical examination demonstrated peri-lesional gliosis
and fibrinoid necrosis of vascular walls, which were the
same findings as observed in usual post-radiation necro-
sis. No malignant cells were observed. Moreover, there
were dilated vascular structures composed of only endo-
thelial cells without collagen or elastic fiber lining in the
Fig. 1 Axial contrast-enhanced MRI brain images showing a small delayed radiation necrosis in the area of a metastatic brain tumor treated by
SRS (a) at initiation of T-DM1 (15 mm), (b) heterogeneous enhancement (42 mm) at 14 months and (c) rapid progression of nodular lesion
(58 mm) at 15 months after initiation of T-DM1. Precontrast CT scan shows heterogeneous high density area in this lesion (d). The lesion is
shown as an area of low cerebral blood volume (CBV) by perfusion CT (e). Photomicrographs of the removed lesion on Hematoxylin and Eosin
(H-E) (f), CD31 (g) and Elastica van Gieson (EVG) (h) immunohistochemical stains. The scale bar represents 500 μm for panel. Hemorrhage and
dilated vessels are shown (f). The area surrounded by white square is focused in f and g. CD31 immunostaining demonstrates endothelial cells
surrounding dilated vascular lumina (g). However, they are not accompanied by perivascular structure, which are demonstrated as lacks of
both black (corresponding to elastic fiber) and dark brown lines (corresponding to collagen fiber) in EVG stain (h)
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hemorrhagic lesions (Fig. 1f to h). She gradually im-
proved in sensory aphasia after surgery.
Case 2
A 45-year-old woman presented with slight disorienta-
tion during follow-up for a brain metastasis treated with
SRS, salvage removal, and salvage stereotactic radiother-
apy. She had received T-DM1 with the aim of palliative
systemic therapy for 15 months. Brain MRI demon-
strated a rapidly enlarging mass lesion of heterogeneous
enhancement with cysts in the right parietal lobe
(Fig. 2a-c). Perfusion CT showed a decrease in CBV in
the solid lesion (Fig. 2d).
Thirteen years earlier, the patient was referred to our
hospital as having metastatic breast cancer with 2.5-
years of disease-free interval from initial breast surgery.
Her breast cancer was invasive ductal carcinoma,
T2N1M0, stage IIB and tumor size was 3 cm × 3.5 cm
at initial surgery. The systemic survey disclosed she was
having systemic lymph node metastases. Biopsy speci-
men from the lymph node revealed luminal-HER2 fea-
ture; ER positive (50 %), PR positive (70 %), HER2
positive (3+) and Ki67 unavailable. She received 10 cy-
cles of weekly paclitaxel with trastuzumab as first-line
chemotherapy for metastatic disease, and then was
maintained by trastuzumab and leuprorelin acetate with
tamoxifen for 2 years. A check-up MRI revealed an
asymptomatic brain metastasis, about 10 mm in diam-
eter, in the right parietal lobe. She underwent SRS
(D95 = 25 Gy). She also received trastuzumab with cap-
ecitabine for newly developed liver metastases for
4 months. A year later, a brain MRI demonstrated
asymptomatic recurrence of the parietal metastasis. She
underwent surgical removal and postoperative stereo-
tactic radiotherapy (SRT) (30 Gy/5 fr) for the lesion be-
cause of tumor invasion into the arachnoid membrane.
The recurrent metastasis had a pathological profile of
ER negative, PR-negative and HER2 positive. She re-
ceived weekly trastuzumab therapy, and added lapatinib
for newly developed ovarian metastasis.
Approximately 14 years after initial diagnosis and
5.5 years after SRT, she received T-DM1. She received
3.6 mg per kilogram of body weight intra venously every
21 days. Her liver and ovarian metastases were then well
controlled. Nine months after the initiation of T-DM1, a
follow-up MRI revealed an asymptomatic cyst and nodu-
lar lesion at the irradiation site (Fig. 2a b), which in-
creased in size consistently in 6 months (Fig. 2c). The
Fig. 2 Axial contrast-enhanced MRI brain images showing a right parietal delayed radiation necrosis (15 mm) after SRS, surgery, and SRT at
initiation of T-DM1 (a), (b) enlarging heterogeneous enhancement (30 mm) at 12 months (c) rapid progression of nodular lesion (48 mm) at
15 months after initiation of T-DM1 therapy. Precontrast CT scan shows high density area in this lesion (d). Perfusion CT (e) showing an area
of low CBV. Photomicrographs of H-E (f), CD31 (g) and EVG (h) stains. The scale bar represents 500 μm for panel. Hemorrhage and dilated
blood containing spaces are shown (f). CD31 immunostaining (g) shows vascular structures of variable sizes. However, EVG stain (g) indicates
no elastic or collagenous fibers surrounding vascular lumina, in contrast to purplish-brown collagen and black elastic fibers comprising septa
between hemorrhagic area (left) and viable cerebral tissue (lower right)
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features of imaging (Fig. 2d) and history of repeated
stereotactic irradiation were consistent with the diagno-
sis of RN. She underwent surgical resection of the lesion
within the safety margin. The pathological examination
demonstrated an organizing hematoma without malig-
nancy. The hematoma was surrounded by fibrous septa
existing in viable cerebral tissue, and contained dilated
vascular structures of various sizes, part of which looked
conglomerated. There were no collagenous or elastic
fiber components surrounding dilated CD31-positive
endothelial lumina (Fig. 2f to h). She improved slight
disorientation after surgery.
Discussion
Delayed RN has been one of the critical problems for
long-term survivors after SRS for brain metastases [4]. A
report by the Radiation Therapy Oncology Group trial
90-05 involved a study of 156 patients with recurrent
primary brain tumors or brain metastases [5]. From this
trial, the group made SRS dose recommendations based
on maximum tumor diameter to limit RN risk. In fact,
dose-volume analysis of complication risk estimates were
reported after SRS for arterio-venous malformations
(AVM) [6, 7]. Recently, RN with “enhanced nodular
lesion and cyst” was reported as a subtype of RN which
develops more than 5 years after SRS for AVM [8, 9]. It
consisted of a rapidly growing nodular lesion and
hematoma, or cysts, causing neurological manifestations.
Here we report two cases of growing nodule plus cyst,
which presented 6 and 8 years after SRS. For both pa-
tients, the nodules plus cysts were associated with treat-
ment of stage IV breast cancer using T-DM1. Each
lesion was identified as a small enhanced mass on MRI
soon after commencement of T-DM1. Neurological de-
terioration, due to rapid growth of the lesion, occurred
in both cases 13 and 14 months later. Pathologically, the
lesions represented a mixture of granulation tissue, ne-
crosis and hemorrhage, with telangiectasia and fibrinoid
degeneration of the small vessels. The triggering role of
T-DM1 in the induction of these lesions is supported by
a chronological relationship between lesion development
and T-DM1 exposure. Similar cases of cutaneous, or
mucosal telangiectasia and hemorrhage have been re-
ported in association with T-DM1 [10].
T-DM1 is an antibody-drug conjugate incorporating
the HER2-targeted antitumor properties of trastuzumab
with the cytotoxic activity of the microtubule-inhibitory
agent DM1. T-DM1 is approved in several countries as a
single agent for HER2 positive metastatic breast cancer
(MBC), which has previously been treated with trastuzu-
mab and a taxane. In a phase III EMILIA trial, T-DM1
significantly prolonged median progression-free survival
(PFS; hazard ratio (HR) = 0.65; P < 0.001; 9.6 versus
6.4 months) and median overall survival (OS; HR = 0.68;
P < 0.001; 30.9 versus 25.1 months) with less toxicity,
compared with lapatinib with capecitabine in patients
with HER2-positive MBC who previously treated with
trastuzumab-based regimen [1]. Several reports have
been published that indicated T-DM1 is also effective
for brain metastasis [11–14]. The mild to moderate, bur
continuous thrombocytopenia (28.0 %) is a common side
effect of T-DM1.
Although the pathophysiology of the growing delayed
RN is not fully understood, several mechanisms are hy-
pothesized. First, an irradiated lesion makes nodular
granulation with cysts slowly over a long period of
time. In addition, the nodule contains abundant neo-
vasculature that can easily cause micro-bleeding into
the cysts, and from that, they can become expansive
hematoma with mass effects [15]. Second, induced tel-
angiectasias by T-DM1 may represent an additional
cause of hemorrhage and growth of the lesion after SRS
[16]. Third, thrombocytopenia by T-DM1 may also en-
hance hemorrhage from abnormal vessels in the lesion,
although thrombocytopenia was not found in our pa-
tients from their T-DM1 treatment.
Furuse et al. reviewed pathologic features of radiation
necrosis from 18 surgically treated patients. They found
necrotic core and enlarged vessels with thin walls, hyali-
nized vessels and reactive astrocytes in surrounding area
[17]. No massive hematomas were reported, though tel-
angiectatic vessels were accompanied by microbleeding
and interstitial edema. In both hemorrhagic lesions of
our cases, there were dilated vascular structures com-
posed of endothelial lining without fibrous components.
However, it remains to be explored whether these thin-
walled vessels would induce hemorrhage or would have
been induced by the certain causes same as those of
hemorrhage.
Before the introduction of trastuzumab, patients with
HER2-positive MBC had very poor prognosis. As such,
adverse events that affected the brain after SRS for brain
metastases were never a problem that needed consider-
ation. However, new targeted agents for HER2-positive
MBC have significantly improved patient long-term sur-
vival. A novel association between T-DM1 and RN in
the brain may be an important factor in the micro-
bleeding adverse events or the mass effect associated
with the use of T-DM1 for patients. These cases high-
light the need to caution when combining radiation
therapy for brain metastases and new systemic targeted
therapies. Our observation suggests a need for a pro-
spective evaluation for brain metastases in patients
treated with T-DM1 after SRS.
Conclusions
While this report is limited in two cases, the correlation
of growing mass lesion in the area of SRS and T-DM1
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treatment was salient. New targeted agents are intro-
duced to clinical use every three weeks, providing new
benefits for patients. SRS is used with increased fre-
quency for small brain metastases, sometimes for
asymptomatic ones. Thorough reporting and evaluation
of adverse effects are essential in the concurrent use of
new modalities.
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